CEDAR KNOLLS, N.J.,
April 24, 2017 /PRNewswire/
-- MYOS RENS Technology Inc. ("MYOS" or "the Company")
(NASDAQ: MYOS), a company focused on the discovery, development and
commercialization of muscle health and performance products,
announced today that it will be a Silver Sponsor at the upcoming
International Conference on Frailty and Sarcopenia Research
(ICFSR), to be held April 27-29, 2017
in Barcelona, Spain. MYOS will be
using this event as a platform for introducing clinicians to Qurr
Well, their new line of functional nutrition products targeted at
improving musculoskeletal health in aging adults.
"We are pleased to be a sponsor at the upcoming International
Conference on Frailty and Sarcopenia Research, and to have the
opportunity to showcase the Qurr Well portfolio of products that
may provide a solution to age-related muscle loss in adults by
increasing lean muscle mass," stated Joseph
Mannello, interim CEO of MYOS. "With this portfolio of
products, MYOS aspires to become one of the leading companies in
the world focused on improving musculoskeletal health in aging
adults."
The ICFSR is the premier medical conference that highlights
advances in sarcopenia research, with over 400 leading physicians
and scientists with expertise in sarcopenia from 62 countries
attending each year. Sarcopenia is defined by the National
Institutes of Health as the progressive and generalized loss of
skeletal muscle mass and function in older adults, and MYOS will be
joining other companies focused on addressing sarcopenia through
therapeutics and nutrition at the conference.
Qurr Well, along with the entire Qurr portfolio of products,
features Fortetropin®, which has been clinically shown to build
lean muscle mass and improve muscle function. Fortetropin® is
MYOS' proprietary ingredient that naturally reduces
myostatin. It is prepared from fertilized egg yolk and is
processed using patented technology to preserve the natural
bioactivity of egg yolk. Results from a double-blind,
placebo-controlled human clinical study with researchers from the
University of Tampa demonstrated
statistically significant gains in muscle thickness relative to
placebo. Qurr products come in shakes and powders and are
available in four flavors.
MYOS will exhibit in booth #2 at ICFSR 2017, and its scientists
will be in attendance to meet with conference delegates to discuss
the Company's latest research findings. For more information or to
purchase Qurr, please visit www.qurr.com.
About MYOS RENS Technology Inc.
MYOS RENS Technology
(MYOS), "The Muscle Company™", is a Cedar
Knolls, NJ-based biotherapeutics and bionutrition company
focused on developing products that improve muscle health and
performance and bringing them to market. MYOS is the owner of
Fortetropin®, the world's first clinically demonstrated
myostatin reducer. Myostatin is a natural regulatory protein, which
inhibits muscle growth and recovery. Fortetropin® is
manufactured to optimize biological activity, which MYOS believes
has the potential to redefine existing standards of physical health
and wellness enhancement.
Forward-Looking Statements
Any statements in this
release that are not historical facts are forward-looking
statements. Actual results may differ materially from those
projected or implied in any forward-looking statements. Such
statements involve risks and uncertainties, including but not
limited to those relating to product and customer demand, market
acceptance of our products, the ability to create new products
through research and development, the successful launch of our
products, including Qurr products, the success of our research and
development, the results of the clinical evaluation of
Fortetropin® and its effects, the ability to enter into
partnership opportunities, the ability to generate the forecasted
revenue stream and cash flow from sales of our products, the
ability to achieve a sustainable, profitable business, the effect
of economic conditions, the ability to protect our intellectual
property rights, competition from other providers and products, the
continued listing of our securities on the Nasdaq Stock Market,
risks in product development, our ability to raise capital to fund
continuing operations, and other factors discussed from time to
time in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to update or revise any
forward-looking statement for events or circumstances after the
date on which such statement is made except as required by law.
These statements have not been evaluated by the Food and Drug
Administration. Our products are not intended to diagnose, treat,
cure or prevent any disease.
Media Contact
MYOS RENS Technology Inc.
Joanne Goodford
(973) 509-0444
jgoodford@myoscorp.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/myos-rens-will-be-silver-sponsor-at-international-conference-on-frailty-and-sarcopenia-research-icfsr-300443680.html
SOURCE MYOS RENS Technology